Covidien is the latest in a line of companies entering the renal denervation business, as it will unveil its new OneShot renal denervation system at the EuroPCR (European Association for Percutaneous Cardiovascular Interventions) congress in Paris, France, on May 16. Like all other recently introduced denervation systems, it is intended to treat patients with hypertension who are not responsive to traditional medical therapy.
The OneShot system is an irrigated, radiofrequency (RF) based balloon catheter used to ablate the renal sympathetic nerves located in the outer wall of the renal arteries. The OneShot technology received CE mark clearance in February 2012. If you are attending EuroPCR, it will be possible to watch two denervation procedures that will be transmitted live from Leipzig, Germany.
Press release: Covidien Introduces New Treatment for Drug-Resistant Hypertension…